# Salmonella Conjugates CVD 2000: Study of Responses to Vaccination With Trivalent Salmonella Conjugate Vaccine to Prevent Invasive Salmonella Disease

> **NCT05525546** · PHASE1 · COMPLETED · sponsor: **University of Maryland, Baltimore** · enrollment: 82 (actual)

## Conditions studied

- Risk Reduction

## Interventions

- **BIOLOGICAL:** Trivalent Salmonella Conjugate Vaccine (TSCV) Full-Strength Formulation
- **BIOLOGICAL:** Trivalent Salmonella Conjugate Vaccine (TSCV) Half-Strength Formulation
- **BIOLOGICAL:** Trivalent Salmonella Conjugate Vaccine (TSCV) Dilutional Half-Strength Formulation
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT05525546
- **Lead sponsor:** University of Maryland, Baltimore
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-08-15
- **Primary completion:** 2023-06-12
- **Final completion:** 2023-06-12
- **Target enrollment:** 82 (ACTUAL)
- **Last updated:** 2023-09-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05525546

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05525546, "Salmonella Conjugates CVD 2000: Study of Responses to Vaccination With Trivalent Salmonella Conjugate Vaccine to Prevent Invasive Salmonella Disease". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT05525546. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*